Targeting MT-MMPs in Cancer Progression

靶向 MT-MMP 在癌症进展中的作用

• 批准号: 7777309
• 负责人: Rafael A. Fridman
• 金额: $ 34.96万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-07-01 至 2014-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7777309
• 关键词: Animal Cancer Model; Attention; Biochemical; Biological; Biological Factors; Cancer Patient; Cause of Death; Chemicals; Detection; Development; Effectiveness; Extracellular Matrix; Foundations; Funding; Gelatinase A; Gelatinase B; Gelatinases; Generations; Goals; In Vitro; Inhibition of Matrix Metalloproteinases Pathway; Laboratories; Libraries; Malignant Neoplasms; Matrix Metalloproteinase Inhibitor; Matrix Metalloproteinases; Mediating; Membrane; Modeling; Molecular; Monitor; Mus; Neoplasm Metastasis; Peptide Hydrolases; Plant Resins; Process; Property; Proteolysis; Reporting; Research; Role; SB 3CT compound; Sampling; System; Testing; Tissues; Tumor Tissue; base; cancer cell; chemical synthesis; clinically significant; design; human MMP14 protein; improved; in vivo; inhibitor/antagonist; neoplastic cell; novel; novel strategies; public health relevance; small molecule; therapeutic target; therapy development; trafficking; tumor; tumor progression

DESCRIPTION (provided by applicant): The studies outlined in this proposal are a continuation of our effort towards achieving the long-term goal of developing novel approaches to selective inhibition of matrix metalloproteinase (MMP) activity during cancer progression. In the previous funding period we focused on the gelatinases, MMP-2 and MMP-9 and we reported the successful development and characterization of the first mechanism-based gelatinase inhibitor, SB-3CT, and demonstrated its effectiveness in various tumor models in mice. Our approach to selective MMP inhibitor design has provided a point of departure for the field. We now propose to develop this approach for effective and selective inhibition of membrane-type MMPs (MT-MMP), a subfamily of membrane-anchored MMPs that has received considerable attention in the last five years due to their key roles in cancer cell invasion. This new information highlights the MT-MMPs as promising therapeutic targets that deserve further exploration. However, to achieve this goal there is critical need for effective and selective MT-MMP inhibitors, which are currently missing. Preliminary evidence from our laboratory demonstrates the development of new mechanism-based MT1-MMP inhibitors with great potential. Also, a novel inhibitor library has been conceived, which will permit discovery of more selective mechanism-based inhibitors for MT-MMPs based on the molecular template of SB-3CT. Finally, to aid in the detection of active MMPs in cancer tissues, we have synthesized and tested an inhibitor-tethered resin, which can be used to ascertain the level of active protease during cancer progression and inhibitor treatment. Here we propose to continue our effort using a comprehensive approach of biochemical and biological studies for identification and inhibition of MT-MMPs. Specifically, we will (1) Identify selective mechanism-based inhibitors for transmembrane MT-MMPs, (2) Validate the inhibitory properties of the MT-MMP inhibitors in cellular systems of MT-MMP-dependent pericellular proteolysis, (3) Test the MT-MMP inhibitors in animal models of cancer, and (4) Monitor active forms of the MT-MMP/gelatinase axis in tumor tissues as a function of tumor development and MT-MMP inhibitor treatment. The results of the present application will contribute to the collective endeavor of developing novel and rational approaches for controlling unregulated proteolysis in cancer tissues mediated by MT-MMPs. PUBLIC HEALTH RELEVANCE: Tumor dissemination and metastasis remain the major cause of death in cancer patients. Therefore, understanding the biological factors promoting these processes and developing therapies aimed at reducing tumor spread is of great clinical significance.

描述（由申请人提供）：本提案中概述的研究是我们努力实现长期目标的延续，即开发在癌症进展期间选择性抑制基质金属蛋白酶（MMP）活性的新方法。在上一个资助期，我们专注于明胶酶，MMP-2和MMP-9，我们报告了第一个基于机制的明胶酶抑制剂SB-3CT的成功开发和表征，并证明了其在小鼠各种肿瘤模型中的有效性。我们的选择性MMP抑制剂设计方法为该领域提供了一个出发点。我们现在建议开发这种方法来有效和选择性地抑制膜型基质金属蛋白酶（MT-MMP），这是一个膜锚定基质金属蛋白酶的亚家族，由于其在癌细胞侵袭中的关键作用，在过去五年中受到了相当大的关注。这一新的信息突出了MT-MMPs作为值得进一步探索的有前途的治疗靶点。然而，为了实现这一目标，迫切需要有效的和选择性的MT-MMP抑制剂，这是目前缺少的。来自我们实验室的初步证据表明，新的机制为基础的MT 1-MMP抑制剂的发展具有巨大的潜力。此外，一个新的抑制剂库已被构思，这将允许发现更多的选择性机制为基础的抑制剂MT-MMPs的分子模板的基础上SB-3CT。最后，为了帮助检测癌组织中的活性MMP，我们合成并测试了一种可用于确定癌症进展和抑制剂治疗过程中活性蛋白酶水平的分子栓系树脂。在这里，我们建议继续我们的努力，使用一个全面的方法的生化和生物学研究的MT-MMPs的识别和抑制。具体而言，我们将（1）鉴定跨膜MT-MMP的基于选择性机制的抑制剂，（2）验证MT-MMP抑制剂在MT-MMP依赖性细胞周蛋白水解的细胞系统中的抑制特性，（3）在癌症动物模型中测试MT-MMP抑制剂，和（4）监测肿瘤组织中MT-MMP/明胶酶轴的活性形式作为肿瘤发展和MT-MMP抑制剂治疗的函数。本申请的结果将有助于开发用于控制由MT-MMPs介导的癌组织中的不受调节的蛋白水解的新的和合理的方法的集体奋进。公共卫生相关性：肿瘤扩散和转移仍然是癌症患者死亡的主要原因。因此，了解促进这些过程的生物学因素并开发旨在减少肿瘤扩散的治疗方法具有重要的临床意义。